Compare BFLY & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFLY | AQST |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 871.5M | 707.6M |
| IPO Year | N/A | 2018 |
| Metric | BFLY | AQST |
|---|---|---|
| Price | $4.07 | $3.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $4.00 | ★ $8.83 |
| AVG Volume (30 Days) | ★ 4.8M | 4.3M |
| Earning Date | 02-27-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $88,447,000.00 | $43,397,000.00 |
| Revenue This Year | $13.77 | N/A |
| Revenue Next Year | $16.00 | $52.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.04 | N/A |
| 52 Week Low | $1.32 | $2.12 |
| 52 Week High | $4.98 | $7.55 |
| Indicator | BFLY | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 67.28 | 22.22 |
| Support Level | $3.67 | $5.86 |
| Resistance Level | $4.29 | $6.59 |
| Average True Range (ATR) | 0.22 | 0.32 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 74.42 | 11.98 |
Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional's pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. The company enables the practical application of ultrasound information in the clinical workflow. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. With its small, handheld size, low cost, and simple user interface.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.